Dr. Matthew John Frigault, MD

Dr. Frigault practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Frigault's NPI, 1013283035, was assigned on March 23, 2012. Dr. Frigault graduated from Perelman School of Med at the University of Pennsylvania in 2012. Dr. Frigault holds Massachusetts license 263070.

Dr. Frigault's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Frigault's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Frigault is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Frigault to 2 more medical groups and 1 community health center, each named with a free account. Dr. Frigault's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Frigault practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Frigault's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Frigault's licenses on file in 2 states: Massachusetts and Maryland.

CMS data shows 662 Medicare services from Dr. Frigault across 4 procedure codes in 2024, for 121 Medicare patients. Medicare paid $64,974 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 121 Medicare patients who saw Dr. Frigault in 2024. The largest group is 65 to 74, with 57 patients. 69% of them have high blood pressure, and 61% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Frigault's median patient age at 71, with 49% women.

In 2024, Dr. Frigault wrote 190 Medicare Part D claims for 47 patients. 92% of them were for generic drugs. CMS names the drug for 79 of them, across 2 drugs with 11 or more claims each, at $564 in total drug cost. In 2023, CMS named 44 claims across 2 drugs.

Dr. Frigault accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 114 papers to Dr. Frigault, published from 2014 to 2025. 2024 was the busiest year, with 19. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and T-Lymphocytes. Dr. Frigault has published most often in Blood. Dr. Frigault's most frequent co-authors are Marcela Valderama Maus, MD, Mark Leick, MD and Caron Alyce Jacobson, MD.

Dmand AI links Dr. Frigault to 7 clinical trials, 3 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Hematologic Neoplasms, Burkitt Lymphoma and Leukemia, Myeloid, Acute.

CMS Open Payments shows 147 general payments to Dr. Frigault from 19 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 93% of the total. Foundation Medicine, Inc. paid the most, $105,144. It also lists 4 research payments totaling $2,281 from 2022 to 2024.

Dr. Frigault graduated from Perelman School of Med at the University of Pennsylvania in 2012.